Echo Therapeutics — Proxy Contest (May 2014)
33 slides from Echo Therapeutics's proxy contest presentation, May 30, 2014
Slide 1: Echo Therapeutics Investor Presentation May 2014
~©echo THERAPEUTICS (Nasdaq: ECTE) Investor Presentation May 2014 ©2014
Slide 2: Forward-looking statements
Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations of Echo The
Slide 3: Echo Therapeutics is a publicly traded medical device company
Echo Therapeutics is a publicly traded (Nasdaq: ECTE) medical device company with expertise in the utilization of non- invasive and wireless technologies Symphony” CGM System * Non-invasive skin permeation = Wireless data transmission = Continuous glucose display «© echo THERAPEUTICS
Slide 4: Significant and growing global market opportunity
= Significant and growing global market opportunity = $1+ billion in critical care in glucose monitoring = Clinically validated = Multiple studies with consistent, favorable results = Extensive U.S. and international IP portfolio = Experienced management team with relevant experience = Strategic pla
Slide 5: Hyperglycemia is common in critically ill patients
= Hyperglycemia is common in critically ill patients (stress hyperglycemia), even in those with no previous history of diabetes, including: = Approximately 28% glucose values >180mg/dL in critically ill patients? = Post-surgical patients, septic patients, trauma patients = Hyperglycemia contributes
Slide 6: Continuous Glucose Monitoring (CGM)
Continuous Glucose Monitoring (CGM) — = Current TGC methods are burdensome and costly: ~2 hours/day? and $200/day per patient? = Intermittent blood glucose measurements leave gaps of time and data between measures = CGM gives a greater view of glucose trends and the direction glucose levels are goin
Slide 7: Estimated global market for hospital-based CGM of $1+ Billion
Estimated global market for hospital-based CGM of $1+ Billion 9, of U.S. and EU hospitals have TGC. 70-90% — of!S.and 30 million U.S. critical care patient days/year? 100,000 U.S. critical care beds* , 18 million EU critical care patient days/year? 60,000 = EVeritical care beds* , + Boston Biomedica
Slide 8: Symphony SkinPrep, Glucose Sensor & Transmitter, Wireless Remote Monitor
Symphony’ SkinPrep Glucose Sensor & Transmitter Wireless Remote Monitor * Removes outer-layer of * Electro-chemical glucose * Graphical display of glucose dead skin, or stratum sensor trend data corneum, to access glucose * Bluetooth transmitter * Customizable early-warning * Patented feedback contr
Slide 9: Rapid, accurate, free of interferences
= Rapid: very little lag between blood glucose and the measured value = Accurate: within FDA accuracy guidelines * Free of interferences: no interferences such as drugs or physiologic perturbations Gapilary Bed * Inert: no reaction with the tissue or formation of coating rendering the device inaccur
Slide 10: Symphony CGM System Revenue Model
Symphony CGM System Revenue Model Disposable Components Sensor Module (sensor/transmitter/base) SkinPrep Tip Expected main revenue driver $75 -150/day estimated price range Durable Components Monitor SkinPrep $3-6k estimated price range 10 ©2014 ‘Conn Prana Date: 20 May 2014
Slide 11: Survey results: ICU nurses and physicians
% Agree (sum) Symphony CGM would be an improvement on current glucose monitoring methods Symphony CGM would improve overall outcomes Symphony CGM would have a positive impact on blood glucose control Symphony CGM's needle-free and non-invasive Sensor is a highly valuable feature 0% 20% 40% 60% 80% 1
Slide 12: CE Mark Regulatory Trial completed November 2013
= CE Mark Regulatory Trial completed November 2013 = 32 post-operative surgical patients in four hospital critical care units = 634 data points compared to YSI analyzer reference measurements = Met safety and efficacy endpoints = 12.5% Mean Absolute Relative Difference (MARD), or error rate = Contin
Slide 13: Broad Intellectual Property Estate
= Broad Intellectual Property Estate = 8U.S. patents, ~70 foreign patents, ~25 patents pending worldwide = Most issued core patents expire mid- to late-2020s = Method and Device Patents cover a broad range of applications: = Glucose sensor and methods = Transdermal analyte extraction and measurement
Slide 14: Management team and key advisors
Name Robert Doman le Executive Chairman and Interim CEO DUSA Pharmaceuticals, Leach Technology Group, Bristol- Myers Squibb, J8d a Chris Schnittker, CPA SVP & CFO Micromet, Cytogen & Sanofi Aventis ‘Walk, TransMedics, Quarry Technologies, Analogic emEEieD Melaka Sae aT Corporation, Siemens Medical S
Slide 15: 2013 Milestones and 2014-2015 Catalysts
2013 Milestones v v v < Completed ISO 13485 Audit Submitted FDA Pre-Submission Package Held FDA Meeting Completed CE Mark Trial Signed Partnership Agreement with Medical Technologies Innovation Asia (MTIA) for China Implemented significant cost reduction measures resulting in millions in annualized
Slide 16: Future opportunities and product enhancements
= Hospital use beyond ICU (general wards) = Integration with vital signs monitor = Integration with insulin dosing software = Outpatient diabetes use = Longer duration sensor life = Reusable transmitter = Integration with insulin pump = New mobile receiver @©ececho 16 THERAPEUTICS
Slide 17: Corporate snapshot
Ticker Nasdaq: ECTE Headquarters Philadelphia Employees ~30 Market Capitalization ~$21 million Share Price (5/20/2014) $1.76 50-day Average Volume ~165,000/day Common Stock 12.0 million Fully Diluted Shares 16.6 million Cash and Cash Equivalents (3/31/2014) $7.1 million Long-term Debt $0.0 @©ececho
Slide 18: The Echo Board is Engaged, Highly Qualified, Open to Stockholder Input
The Echo Board is Engaged, Highly Qualified, Open to Stockholder Input = Echo has a strong independent Board = Echo has a presiding lead independent director = Interim CEO is the only management director, with 4 outside directors = 4of our 5 directors (80%) are considered independent = The Board is
Slide 19: Why the Platinum Group is WRONG for Echo
Why the Platinum Group is WRONG for Echo The Platinum Group’s Board nominee, Shepard M. Goldberg, is not the right choice for the Echo Board and his extensive experience for the majority of his career at a privately-held swimming pool company is not the kind of experience Echo needs @©ececho 19 THER
Slide 20: The Dissident Group
The Dissident Group * The Platinum Group is a dissident stockholder group led by Platinum Management (NY) LLC, a hedge fund based in New York City that was founded by Mark Nordlicht in 2003. * The Platinum Group beneficially owns 19.9% of Echo's common stock and has filed a Scheduled 13D with the SE
Slide 21: Board rejected Shepard Goldberg's candidacy
= Before Michael Goldberg was appointed to Echo's Board, Platinum had sought to have his first cousin and longtime business associate, Shepard Goldberg, appointed. Platinum only named Michael Goldberg as its designee after the Board informed Platinum that, after interviewing Mr. Goldberg and reviewi
Slide 22: eee cr anne
eee cr anne = Rebuffed in its attempt to have Shepard Goldberg appointed to the Board earlier this year, the Platinum Group is seeking through its costly, disruptive and self-serving proxy contest to have Mr. Goldberg elected to the Echo Board, in opposition to our highly qualified and very experien
Slide 23: ae a ss a
ae a ss a = We do not believe that the Platinum Group is merely seeking to have two out of five representatives on the Echo Board but rather is seeking to eventually replace the entire Echo Board. = Based on the Platinum Group’s choice of a nominee, we do not believe this proxy contest is about any
Slide 24: The Choice Before Stockholders - Robert F. Doman
The Choice Before Stockholders - The Echo Board's Highly Qualified and Very Experienced Nominee - Robert F. Doman: = Mr. Doman became a member of the Board in March 2013 and, since August 2013, has been serving as Echo's Executive Chairman and Interim Chief Executive Officer. = Mr. Doman has over 30
Slide 25: The Choice Before Stockholders - Shepard M. Goldberg
The Choice Before Stockholders - The Platinum Group’s Nominee - Shepard M. Goldberg: Mr. Goldberg has spent the majority of his career with a small, privately-held heating / swimming pool products company. We believe that Mr. Goldberg brings to the Board no relevant medical device experience. Shepar
Slide 26: The Choice Before Stockholders - Shepard M. Goldberg (cont'd)
The Choice Before Stockholders - The Platinum Group’s Nominee - Shepard M. Goldberg (cont'd): = Shepard Goldberg's board experience is limited to companies where either Michael Goldberg or Platinum was an investor. = Two of the companies, Cordex Pharma, Inc. and Emisphere Technologies, Inc., where M
Slide 27: The Choice Before Stockholders
The Choice Before Stockholders - This proxy contest ultimately comes down to the choice between electing = Robert F. Doman, our highly qualified and very experienced director, who brings to Echo's five- member Board over 30 years of executive level, international and domestic management, business de
Slide 28: Interests of the Platinum Group are not aligned with stockholders
We Do Not Believe that the Interests of the Platinum Group are Aligned with * PLATINUM WANTS TO PREVENT ECHO FROM ACCESSING FUTURE GROWTH CAPITAL: The Platinum Group has publicly stated that it wants to prevent Echo from conducting any future debt or equity financings to prevent its 19.9% interest i
Slide 29: Platinum seeks to force stockholders to pay for its proxy contest
We Do Not Believe that the Interests of the Platinum _ are = with = PLATINUM IS SEEKING TO FORCE OTHER STOCKHOLDERS TO PAY FOR ITS COSTLY AND DISRUPTIVE PROXY CONTEST. * the Platinum Group has indicated in its proxy statement that, if it is successful in having its hand-picked nominee, Shepard Goldb
Slide 30: We Reached Out to the Platinum Group in an attempt to Settle
We Reached Out to the Platinum _ in an a to Settle = The Echo Board reached out to the Platinum Group in an attempt to discuss a reasonable settlement and avoid a costly proxy contest. = What was the response? NO RESPONSE TO THE ECHO BOARD'S LETTER, NO INDICATION THAT PLATINUM GROUP IS WILLING TO EN
Slide 31: This proxy contest comes down to a simple choice
This proxy contest ultimately comes down to a simple choice — electing either: + Robert F. Doman, our highly qualified and very experienced director, who brings to Echo's five-member Board over 30 years of executive level, international and domestic management, business development, commercializatio
Slide 32: Vote each and every WHITE proxy card
VOTE EACH AND EVERY WHITE PROXY CARD THAT YOU RECEIVE DON’T ALLOW THE PLATINUM GROUP @©ececho 2 THERAPEUTICS
Slide 33: Proxy solicitation notice
In connection with the solicitation of proxies, Echo Therapeutics, Inc. has filed with the SEC and mailed to stockholders on or about May 9, 2014 a definitive proxy statement in connection with its 2014 Annual Meeting of Stockholders. Echo, its directors, nominees for director and certain officers,